pathway from head to neck and vice-versa.' Efferent axons ascend to brainstem nuclei. The raphe nuclei and locus coeruleus project rostrally to the cortex, and caudally as part of the endogenous pain control circuit.' Stimulation of these brainstem nuclei and of the trigeminal complex increases extracranial blood flow by reflex connection with the parasympathetic part of the facial nerve -via the greater superficial petrosal nerve, sphenopalatine and optic ganglia. This constitutes a link between neural and vascular mechanisms, the "trigemino-vascular reflex". 3 5-HT1 agonists (for example ergotamine, sumatriptan) bind to vascular receptors and constrict dural and pial vessels. Plasma extravasation (PE) can be stimulated by perivascular sensory fibres which release neurokinin A, calcitonin G related peptide (CGRP) and substance P. These neuropeptides, present in unmyelinated C fibres, can be released by antidromic trigeminal stimulation from perivascular sensory axons; this induces vasodilatation and extravasation of plasma protein (neurogenic inflammation) with an increase in CGRP in the superior sagittal sinus. 4 If pretreatment with dihydroergotamine and sumatriptan is given, the levels of CGRP in plasma are reduced, thus providing an explanation for blockade of neurogenic inflammation, the putative cause of pain.
Second order neurons can be suppressed by experiment- Migraine attacks are not well understood, but depend on a primarily cerebral (neural) mechanism with a fluctuating threshold6 which determines the timing and pattern of attacks, the aura, and the consequent changes in pial microcirculation. This is linked to a vascular mechanism which accounts for the headache.45
The release of pain producing vasogenic amines from blood vessel walls are accompanied by pulsatile distension which may account for vascular pain. This is evoked by neural triggers which may activate the trigeminovascular reflex2 (vide supra). Burnstock's "purinergic" hypothesis7
suggests that adenosine 5'-triphosphate (ATP) and its breakdown products adenosine 5' monophosphate and adenosine mediate the vasodilatation following the initial vasospasm. ATP stimulates primary afferent terminals in the cerebral vasculature. Studies have shown that the ATP induced cerebral vasodilatation depends on the endothelium being activated by P(2y)-purinoceptors on the endothelial cell surface and subsequently releasing endothelium-derived relaxing factor (EDRF). Endothelial cells are the main source of the ATP, although adenosine 5'-diphosphate and ATP released from clumped platelets may produce vasodilatation. A purinergic mechanism may also be involved in the initial local vasospasm, via P(2x)-purinoceptors on smooth muscle cells occupied by ATP released either as a cotransmitter with noradrenaline from perivascular sympathetic nerves or from damaged endothelial cells.
The aura is associated with regional spreading oligaemia ( The importance of 5-HT receptors is confirmed by the observations that intravenous 5-HT relieves headache; reserpme (a 5-HT depletor) induces headache; and by the demonstrated efficacy of the 5-HT2 antagonists, methysergide and pizotifen, as prophylactics,"7 and of ergotamine and sumatriptan (both 5-HTI agonists) in treatment of acute attacks. But it is simplistic to regard migraine as a "low serotonin syndrome".
The fashionable neuro-excitatory chemicals, glutamate and aspartate (NMDA) have been investigated as putative initiators of "spreading depression" both between and during attacks. Higher blood levels were found between attacks in both migraine groups compared with tension headache and control subjects. Further elevations of glutamic acid were found during attacks.'8 The results suggest a defective cellular reuptake mechanism for glutamate and aspartate in patients with, migraine which may indicate a similar defect in neurons and glia predisposing the brain of those with migraine to Leao's spreading depression.
Olesen has reconciled the vascular and neurogenic elements as a "vascular-supraspinal-myogenic model". Headache intensity is determined by the sum of nociception from cranial arteries and pericranial myofascial tissues which converge upon the same neurons and are under supraspinal facilitatory control. Vascular input dominates myofascial input in migraine,'9 and vice versa in tension headache. Long term potentiation due to nociceptive activation and sensitisation of neurons may lower the threshold to headache.
The rationale for the use of drugs acting on 5-HT mechanisms depends on the presence of receptors for 5-HT in cranial arteries and elsewhere in the CNS, where they play a role in the neural control of cranial vessels and endogenous pain control systems (vide supra). Since migraine symptoms reflect both neural and vascular phenomena it is likely that 5-HT receptor activity is but one relevant factor. It is probable that many prophylactics act by central 5-HT2 antagonism, whereas control of an attack relies on constriction of cranial vessels mediated by 20 
5-HT, receptors.
Research on sumatriptan has helped to clarify 5-HT receptor functions and diversity, and has contributed to our still incomplete understanding of the pathogenesis of headache. Sumatriptan is a specific and selective agonist of 5-HTI receptors of cranial blood vessels causing vasoconstriction.2' It has negligible effects on 5HT2, 5-HT3, dopaminergic, muscarinic or noradrenergic receptors (compared with ergotamine). Sumatriptan does not penetrate the blood-brain barrier and has no CNS effects. Systemically, it has no effect on pulse or blood pressure. It selectively reduces flow in the internal carotid arteries and in cranial and dural vessels. Intravenous sumatriptan does not change rCBF; it constricts the carotid vascular bed, but has no effect on pial vessels in cats. It has 96% bioavailability subcutaneously and 14% orally, with a plasma half-life of 2 hours. Its clearance is 80% by the liver, 20% by the kidneys where it is excreted as an indole acetic acid analogue.
Early trials of the subcutaneous preparation in a 6 mg dose22 showed relief of headache in 77% patients at 60 minutes, and in 83% at 2 hours with corresponding improvement in nausea, vomiting and photophobia. It is also effective in cluster headache with relief of symptoms at 15 minutes in 74% compared with 26% given placebo.23
The subcutaneous preparation will almost certainly be superseded by oral medication (100 mg) which provides relief in about 70% of attacks within two hours. Second and third attacks respond as well as the first. Comparative trials have shown slight, but significant superiority to aspirin 900 mg plus metoclopramide 1Omg. Legg 
